Roche Holding AG (SWX:ROG)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 257.46B +7.1% |
| Revenue (ttm) | 63.36B +1.5% |
| Net Income | 12.88B +55.6% |
| EPS | 16.04 +55.6% |
| Shares Out | 795.62M |
| PE Ratio | 20.09 |
| Forward PE | 16.04 |
| Dividend | 9.80 (3.04%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 778,976 |
| Open | 322.00 |
| Previous Close | 320.70 |
| Day's Range | 317.40 - 323.50 |
| 52-Week Range | 231.90 - 374.90 |
| Beta | 0.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 24, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases,... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial StatementsNews
Drugmakers race to find a place in the next wave of obesity drugs
Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent Am...
Roche Secures FDA Approval For First PTEN IHC Companion Diagnostic In Prostate Cancer
(RTTNews) - Roche (RHHBY) announced that the VENTANA PTEN (SP218) RxDx Assay has become the first immunohistochemistry (IHC) companion diagnostic test to receive approval from the U.S. Food and Drug A...
Roche and Nestlé fear talent crunch as Switzerland puts population cap to the polls
The proposed 10 million person limit could ruin Switzerland’s reputation as a business hub and risks harming one of Europe’s strongest economies, business leaders warn.
Roche’s global survey highlights urgent need to shift diabetes care from disease treatment to mental wellbeing
[The content of this article has been produced by our advertising partner.] Nearly one in ten people in Hong Kong now live with diabetes, and the city’s burden is growing. An ageing population, shifti...
Roche 's VENTANA MMR RxDx Panel Gains IVDR Approval Across Multiple Cancer Types
(RTTNews) - Roche (RHHBY) has secured European Union In Vitro Diagnostic Regulation (IVDR) approval for expanded use of its VENTANA MMR RxDx Panel, a companion diagnostic designed to help identify can...
Roche (RHHBY) Seeks FDA Approval for Tecentriq in Colon Cancer Treatment
Roche (RHHBY) Seeks FDA Approval for Tecentriq in Colon Cancer Treatment
FDA Grants Priority Review for Genentech's Tecentriq for a Certain Type of Stage III Colon Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the com...
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies
Used as a predictive biomarker, the first-of-its-kind VENTANA MMR RxDx Panel helps identify cancer patients eligible for treatment with certain precision oncology therapies By evaluating a panel of MM...
FDA grants Priority Review for Roche's Tecentriq for a certain type of stage III colon cancer
Basel, 11 June 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) f...
The Zacks Analyst Blog Highlights Amazon.com, Bank of America, Roche, Oak Valley Bancorp and Ohio Valley Banc
Amazon, Bank of America and Roche are in focus as Zacks highlights growth drivers, expansion plans and product momentum across key businesses.
Roche (RHHBY) Commits to â¬600M Diagnostics Facility in Germany Amid Cost-Cutting Concerns
Roche (RHHBY) Commits to â¬600M Diagnostics Facility in Germany Amid Cost-Cutting Concerns
Roche sticks to German investment after Eli Lilly cuts
The Swiss pharmaceutical and diagnostics giant Roche said it is sticking to its planned investments in Germany, unlike some of its competitors that have scaled back spending in the country.
Top Stock Reports for Amazon, Bank of America & Roche
Amazon's AI push, sales outlook and diversified revenue streams stand out, while Bank of America and Roche navigate growth drivers and key risks.
This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug
Nurix Therapeutics strikes an agreement with Roche to commercialize its lead asset, bexobrutideg.
Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying
Nurix Therapeutics stock bounded of its 50-day line Monday after inking a deal with Roche for its BTK-degrading drug, bex-deg.
NRIX Soars 38% on $2.3B Licensing Deal with Roche
NRIX Soars 38% on $2.3B Licensing Deal with Roche
Nurix Therapeutics (NRIX) Partners with Roche in $3B Collaboration
Nurix Therapeutics (NRIX) Partners with Roche in $3B Collaboration
Roche enters $2 billion cancer drug agreement with Nurix Therapeutics
Swiss pharmaceutical giant Roche has entered an exclusive licensing and collaboration agreement with Nurix Therapeutics of up to $2.3 billion, the company said on Monday.
Roche And Nurix Ink $2.3 Bln Collaboration To Co-Develop BTK Degrader Bexobrutideg
(RTTNews) - Roche (RHHBY) announced it has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics, Inc. (NRIX). The two companies will co-develop and co-commercialise ...
Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics
The Swiss drugmaker said it would pay Nurix $700 million upfront, while development costs would be split 60-40, with Roche taking the larger share.
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Strategic collaboration combines Nurix's leadership in targeted protein degradation with Roche's portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust clini...
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignancies Collaboration adds to Roche's oncology pipeline and offers potential indica...
Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial
Roche said on Friday that patients lost 22.7% of their body weight in a mid-stage trial of its dual-acting experimental obesity drug, with more than a quarter of those who received the highest dose a...
Zealand touts promising tolerability data for obesity drug in mid-stage study
Zealand Pharma said on Friday its experimental obesity drug, co-developed with Swiss partner Roche , showed encouraging tolerability in a mid-stage trial, bolstering its push to take on market leader...
Roche Develops Ebola PCR Test In Six Days Amid Bundibugyo Outbreak
(RTTNews) - Roche (RHHBY) has announced the rapid development of a Research Use Only (RUO) PCR test to detect the rare Ebola Bundibugyo virus, completing the assay within just six days of the genome s...